240 related articles for article (PubMed ID: 30442199)
1. Anterior chamber fibrinoid syndrome after cataract extraction in a patient on ibrutinib for B-cell chronic lymphocytic leukemia: a case report and review of the literature.
Kolomeyer AM; Hwang CK; Kim BJ
J Med Case Rep; 2018 Nov; 12(1):349. PubMed ID: 30442199
[TBL] [Abstract][Full Text] [Related]
2. Ibrutinib-associated tumor lysis syndrome in chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle cell lymphoma: A case series and review of the literature.
Titus-Rains KS; Brown JN; Hammond JM
J Oncol Pharm Pract; 2018 Oct; 24(7):544-549. PubMed ID: 28714377
[TBL] [Abstract][Full Text] [Related]
3. Effect of prophylactic intraocular pressure-lowering medication on pain during cataract surgery.
Ulaş F; Balbaba M; Çelebi S
J Ocul Pharmacol Ther; 2013 Sep; 29(7):658-62. PubMed ID: 23461283
[TBL] [Abstract][Full Text] [Related]
4. Latanoprost versus timolol gel to prevent ocular hypertension after phacoemulsification and intraocular lens implantation.
Lai JS; Chua JK; Leung AT; Lam DS
J Cataract Refract Surg; 2000 Mar; 26(3):386-91. PubMed ID: 10713234
[TBL] [Abstract][Full Text] [Related]
5. Descriptive analysis of dosing and outcomes for patients with ibrutinib-treated relapsed or refractory chronic lymphocytic leukemia in a Canadian centre.
Uminski K; Brown K; Bucher O; Hibbert I; Dhaliwal DH; Johnston JB; Geirnaert M; Dawe DE; Banerji V
Curr Oncol; 2019 Oct; 26(5):e610-e617. PubMed ID: 31708654
[TBL] [Abstract][Full Text] [Related]
6. Hair and Nail Changes During Long-term Therapy With Ibrutinib for Chronic Lymphocytic Leukemia.
Bitar C; Farooqui MZ; Valdez J; Saba NS; Soto S; Bray A; Marti G; Wiestner A; Cowen EW
JAMA Dermatol; 2016 Jun; 152(6):698-701. PubMed ID: 26982511
[TBL] [Abstract][Full Text] [Related]
7. Ibrutinib-associated sever skin toxicity: A case of multiple inflamed skin lesions and cellulitis in a 68-year-old male patient with relapsed chronic lymphocytic leukemia - Case report and literature review.
Ghasoub R; Albattah A; Elazzazy S; Alokka R; Nemir A; Alhijji I; Taha R
J Oncol Pharm Pract; 2020 Mar; 26(2):487-491. PubMed ID: 31216242
[TBL] [Abstract][Full Text] [Related]
8. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.
Barr PM; Robak T; Owen C; Tedeschi A; Bairey O; Bartlett NL; Burger JA; Hillmen P; Coutre S; Devereux S; Grosicki S; McCarthy H; Li J; Simpson D; Offner F; Moreno C; Zhou C; Styles L; James D; Kipps TJ; Ghia P
Haematologica; 2018 Sep; 103(9):1502-1510. PubMed ID: 29880603
[TBL] [Abstract][Full Text] [Related]
9. Ibrutinib rash in a patient with 17p del chronic lymphocytic leukemia.
Mannis G; Wu D; Dea T; Mauro T; Hsu G
Am J Hematol; 2015 Feb; 90(2):179. PubMed ID: 24890909
[No Abstract] [Full Text] [Related]
10. Intracameral triamcinolone acetonide to control postoperative inflammation following cataract surgery with phacoemulsification.
Karalezli A; Borazan M; Akova YA
Acta Ophthalmol; 2008 Mar; 86(2):183-7. PubMed ID: 18162061
[TBL] [Abstract][Full Text] [Related]
11. The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia.
Hallek M; Kay NE; Osterborg A; Chanan-Khan AA; Mahler M; Salman M; Wan Y; Sun S; Zhuang SH; Howes A
Future Oncol; 2015; 11(1):51-9. PubMed ID: 24901734
[TBL] [Abstract][Full Text] [Related]
12. Dose-limiting stomatitis associated with ibrutinib therapy: a case series.
Vigarios E; Beylot-Barry M; Jegou MH; Oberic L; Ysebaert L; Sibaud V
Br J Haematol; 2019 May; 185(4):784-788. PubMed ID: 30408164
[No Abstract] [Full Text] [Related]
13. Intraindividual comparison of the effects of a fixed dorzolamide-timolol combination and latanoprost on intraocular pressure after small incision cataract surgery.
Rainer G; Menapace R; Findl O; Petternel V; Kiss B; Georgopoulos M
J Cataract Refract Surg; 2001 May; 27(5):706-10. PubMed ID: 11377900
[TBL] [Abstract][Full Text] [Related]
14. Effect of antiglaucoma agents on postoperative intraocular pressure after cataract surgery with Viscoat.
Borazan M; Karalezli A; Akman A; Akova YA
J Cataract Refract Surg; 2007 Nov; 33(11):1941-5. PubMed ID: 17964402
[TBL] [Abstract][Full Text] [Related]
15. Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare.
Hampel PJ; Call TG; Ding W; Muchtar E; Kenderian SS; Wang Y; Leis JF; Witzig TE; Koehler AB; Fonder AL; Schwager SM; Rabe KG; Van Dyke DL; Braggio E; Slager SL; Kay NE; Parikh SA
Am J Hematol; 2020 Mar; 95(3):E57-E60. PubMed ID: 31788844
[No Abstract] [Full Text] [Related]
16. [Prevention of early postoperative increase in intraocular pressure after phacoemulsification. Comparison of different antiglaucoma drugs].
Schwenn O; Xia N; Krummenauer F; Dick HB
Ophthalmologe; 2001 Oct; 98(10):934-43. PubMed ID: 11699314
[TBL] [Abstract][Full Text] [Related]
17. Ibrutinib-induced polyneuropathy: A case report.
Cömert P; Albayrak M; Yıldız A; Şahin O; Öztürk HB; Reis Aras M
J Oncol Pharm Pract; 2020 Sep; 26(6):1501-1504. PubMed ID: 32028841
[TBL] [Abstract][Full Text] [Related]
18. An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure.
Hatanaka M; Grigera DE; Barbosa WL; Jordao M; Susanna R
J Glaucoma; 2008 Dec; 17(8):674-9. PubMed ID: 19092465
[TBL] [Abstract][Full Text] [Related]
19. What should standard frontline therapy be in older patients with chronic lymphocytic leukemia? Ibrutinib should be standard frontline therapy.
Woyach JA
Clin Adv Hematol Oncol; 2016 May; 14(5):330-3. PubMed ID: 27379693
[No Abstract] [Full Text] [Related]
20. Effect of topical pressure-lowering medication on prevention of intraocular pressure spikes after intravitreal injection.
El Chehab H; Le Corre A; Agard E; Ract-Madoux G; Coste O; Dot C
Eur J Ophthalmol; 2013; 23(3):277-83. PubMed ID: 23161177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
